Cilnidipine nanocrystals; Formulation, characterization  and bioavailability study

N.A.

Makale detayları

Cilnidipine nanocrystals; Formulation, characterization and bioavailability study

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Sciences

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.2057-2067

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001334779

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Cilnidipine a fourth generation calcium channel blockers, it was utilized to reduce cardiovascular events. Since cilnidipine is a material classified as Biopharmaceutics Classification System BCS Class-II, which is extremely poorly soluble and has a high permeability in turn low bioavailability. Thus, by employing solvent anti-solvent technology, cilnidipine CLD can be produced as nanocrystals NCs. Getting beyond those obstacles could boost the materials solubility and bioavailability. A pair of distinct stabilizers Soluplus and Tween20 in a ratio of CLD: Soluplus : Tween20 1:0.25:0.5 were used to prepare cilnidipine nanocrystals CLD NCs. Rats were used to evaluate and assess the pharmacokinetics in vivo parameters of CLD and CLD NCs. The optimal formula that was created revealed 62.1 nm with 0.18, which represent particle size and polydispersity index PDI, respectively. At 6 minutes, 99 of CLD NCs were released in phosphate buffer 6.8. It is evident that CLD NCs had a higher relative bioavailability by around 3.17 times and that their area under the concentration time curve AUC and CPmax were greater than those of bulk CLD. Additionally, the CLD NCs Tmax was lower than that of the CLD pure medication. Accordingly, it was evident from the observed pharmacokinetic parameters AUC, CPmax, and Tmax that the CLD NCs enhanced the the oral bioavailability of CLD in rats.

 Cilnidipine a fourth generation calcium channel blockers, it was utilized to reduce cardiovascular events. Since cilnidipine is a material classified as Biopharmaceutics Classification System BCS Class-II, which is extremely poorly soluble and has a high permeability in turn low bioavailability. Thus, by employing solvent anti-solvent technology, cilnidipine CLD can be produced as nanocrystals NCs. Getting beyond those obstacles could boost the materials solubility and bioavailability. A pair of distinct stabilizers Soluplus and Tween20 in a ratio of CLD: Soluplus : Tween20 1:0.25:0.5 were used to prepare cilnidipine nanocrystals CLD NCs. Rats were used to evaluate and assess the pharmacokinetics in vivo parameters of CLD and CLD NCs. The optimal formula that was created revealed 62.1 nm with 0.18, which represent particle size and polydispersity index PDI, respectively. At 6 minutes, 99 of CLD NCs were released in phosphate buffer 6.8. It is evident that CLD NCs had a higher relative bioavailability by around 3.17 times and that their area under the concentration time curve AUC and CPmax were greater than those of bulk CLD. Additionally, the CLD NCs Tmax was lower than that of the CLD pure medication. Accordingly, it was evident from the observed pharmacokinetic parameters AUC, CPmax, and Tmax that the CLD NCs enhanced the the oral bioavailability of CLD in rats.

 Cilnidipine a fourth generation calcium channel blockers, it was utilized to reduce cardiovascular events. Since cilnidipine is a material classified as Biopharmaceutics Classification System BCS Class-II, which is extremely poorly soluble and has a high permeability in turn low bioavailability. Thus, by employing solvent anti-solvent technology, cilnidipine CLD can be produced as nanocrystals NCs. Getting beyond those obstacles could boost the materials solubility and bioavailability. A pair of distinct stabilizers Soluplus and Tween20 in a ratio of CLD: Soluplus : Tween20 1:0.25:0.5 were used to prepare cilnidipine nanocrystals CLD NCs. Rats were used to evaluate and assess the pharmacokinetics in vivo parameters of CLD and CLD NCs. The optimal formula that was created revealed 62.1 nm with 0.18, which represent particle size and polydispersity index PDI, respectively. At 6 minutes, 99 of CLD NCs were released in phosphate buffer 6.8. It is evident that CLD NCs had a higher relative bioavailability by around 3.17 times and that their area under the concentration time curve AUC and CPmax were greater than those of bulk CLD. Additionally, the CLD NCs Tmax was lower than that of the CLD pure medication. Accordingly, it was evident from the observed pharmacokinetic parameters AUC, CPmax, and Tmax that the CLD NCs enhanced the the oral bioavailability of CLD in rats.

 Cilnidipine a fourth generation calcium channel blockers, it was utilized to reduce cardiovascular events. Since cilnidipine is a material classified as Biopharmaceutics Classification System BCS Class-II, which is extremely poorly soluble and has a high permeability in turn low bioavailability. Thus, by employing solvent anti-solvent technology, cilnidipine CLD can be produced as nanocrystals NCs. Getting beyond those obstacles could boost the materials solubility and bioavailability. A pair of distinct stabilizers Soluplus and Tween20 in a ratio of CLD: Soluplus : Tween20 1:0.25:0.5 were used to prepare cilnidipine nanocrystals CLD NCs. Rats were used to evaluate and assess the pharmacokinetics in vivo parameters of CLD and CLD NCs. The optimal formula that was created revealed 62.1 nm with 0.18, which represent particle size and polydispersity index PDI, respectively. At 6 minutes, 99 of CLD NCs were released in phosphate buffer 6.8. It is evident that CLD NCs had a higher relative bioavailability by around 3.17 times and that their area under the concentration time curve AUC and CPmax were greater than those of bulk CLD. Additionally, the CLD NCs Tmax was lower than that of the CLD pure medication. Accordingly, it was evident from the observed pharmacokinetic parameters AUC, CPmax, and Tmax that the CLD NCs enhanced the the oral bioavailability of CLD in rats.

Makale detayları

Cilnidipine nanocrystals; Formulation, characterization and bioavailability study

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Sciences

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.2057-2067

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001334779

pISSN:

2630-6344

Cilnidipine

Soluplus

Nanocrystals

Tween20

solvent anti-solvent

Sayı

Makale detayları

Cilnidipine nanocrystals; Formulation, characterization and bioavailability study

Yazarlar: N.A.

Yayıncı: Marmara University

Ana Başlıklar: Pharmaceutical Sciences

Dergi: Journal of Research in Pharmacy Vol.28 Issue 6, pp.2057-2067

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001334779

pISSN: 2630-6344

Cilnidipine

Soluplus

Nanocrystals

Tween20

solvent anti-solvent

Sayı

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Sciences

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.2057-2067

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001334779

pISSN:

2630-6344